These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16649823)

  • 21. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings.
    Simon NM; Connor KM; LeBeau RT; Hoge EA; Worthington JJ; Zhang W; Davidson JR; Pollack MH
    Psychopharmacology (Berl); 2008 May; 197(4):675-81. PubMed ID: 18246327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
    Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
    Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.
    Reeves H; Batra S; May RS; Zhang R; Dahl DC; Li X
    J Clin Psychiatry; 2008 Aug; 69(8):1228-1236. PubMed ID: 18681749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.
    Barbee JG; Conrad EJ; Jamhour NJ
    J Clin Psychiatry; 2004 Jul; 65(7):975-81. PubMed ID: 15291687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders.
    Pignon B; Tezenas du Montcel C; Carton L; Pelissolo A
    Curr Psychiatry Rep; 2017 Nov; 19(12):103. PubMed ID: 29110139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial.
    Ball S; Marangell LB; Lipsius S; Russell JM
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():217-21. PubMed ID: 23313564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    Simon JS; Nemeroff CB
    J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open-label risperidone for Asperger's disorder: negative symptom spectrum response.
    Rausch JL; Sirota EL; Londino DL; Johnson ME; Carr BM; Bhatia R; Miller S
    J Clin Psychiatry; 2005 Dec; 66(12):1592-7. PubMed ID: 16401163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label trial of nefazodone in high comorbidity panic disorder.
    DeMartinis NA; Schweizer E; Rickels K
    J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis.
    de Vries YA; Roest AM; Burgerhof JGM; de Jonge P
    Depress Anxiety; 2018 Jun; 35(6):515-522. PubMed ID: 29659102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown anxiety disorders research program.
    Salzman C; Goldenberg I; Bruce SE; Keller MB
    J Clin Psychiatry; 2001 Mar; 62(3):149-52. PubMed ID: 11305698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antidepressant effects of risperidone and olanzapine in bipolar disorder.
    McIntyre RS; Mancini DA; Srinivasan J; McCann S; Konarski JZ; Kennedy SH
    Can J Clin Pharmacol; 2004; 11(2):e218-26. PubMed ID: 15520475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis.
    Sajatovic M; Mullen JA; Sweitzer DE
    J Clin Psychiatry; 2002 Dec; 63(12):1156-63. PubMed ID: 12523876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label naturalistic study.
    Gabriel A
    Clin Ter; 2011; 162(2):113-8. PubMed ID: 21533316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
    Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder.
    Rothbaum BO; Killeen TK; Davidson JR; Brady KT; Connor KM; Heekin MH
    J Clin Psychiatry; 2008 Apr; 69(4):520-5. PubMed ID: 18278987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study.
    Papp LA
    J Clin Psychiatry; 2006 Oct; 67(10):1573-6. PubMed ID: 17107249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
    Jensen JB; Kumra S; Leitten W; Oberstar J; Anjum A; White T; Wozniak J; Lee SS; Schulz SC
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):317-26. PubMed ID: 18759641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.